We’ve been speaking about this issue on behalf of our lymphoma colleagues since late August.
But yesterday’s New York Times (Alex Berenson) and Wall Street Journal’s Health Blog (Jacob Goldstein) brought greater awareness to the issue of Medicare’s proposal to cut reimbursement for “smart-bomb” radioimmunotherapies for lymphomas. So far, it appears that Medicare will move forward with plans to cut reimbursements for two RIT drugs, Bexxar® and Zevalin®, to less than their acquisition costs to hospitals.
This issue had already mobilized Newsweek’s Jonathan Alter to write a piercing screed against Medicare over this issue and momentum has been growing to challenge this misguided proposal by CMS (Centers for Medicare and Medicaid Services).
Besides denying lymphoma patients of two drugs with tremendous, life-prolonging activity, there are legitimate concerns that the Medicare proposal will cause the pharmaceutical industry to think twice before investing R&D dollars in lymphoma therapies.
The NYT quoted Dr Mark Kaminski, now of the University of Michigan, who helped discover Bexxar 20 years ago:
“If you can’t get two products that basically hit home runs into the marketplace, there’s very little incentive for further development,” Dr. Kaminski said.
For previous discussion of this issue, see our posts:
and that of our ScienceBlogs colleague, Orac:
Medicare to lymphoma patients: Go screw yourselves